Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...